Chemoprophylaxis for the Hip Fracture Patient: A Comparison of Warfarin and Low-Molecular-Weight Heparin.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 31008818.
- Also identified by DOI 10.1097/BOT.0000000000001435.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To compare the rates of deep venous thrombosis (DVT), rates of pulmonary embolus (PE), and complication profiles of warfarin and low-molecular-weight heparin (LMWH) in patients undergoing operative fixation of hip fractures. Retrospective cohort study. Insurance-based database of more than 22 million patient records. Adult hip fracture patients who were treated operatively and received chemoprophylaxis from 2007 to 2016. A total of 7594 patients met inclusion criteria and were available for final analysis. Pharmacological anticoagulation with warfarin or LMWH to prevent postoperative venous thromboembolism after hip fracture surgery. Development of DVT or PE within 30 and 90 days of surgery. Patients prescribed warfarin had higher rates of DVT and PE compared with those prescribed LMWH. Patients on warfarin were more likely to develop a postoperative hematoma and to be readmitted within 30 and 90 days compared with those on LMWH. Patients in both groups had similar rates of total complications. Patients prescribed warfarin after hip fractures had higher rates of DVT and PE compared with those prescribed LMWH, although both agents had similar complication profiles. Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
Medical subject headings
- Chemoprevention
- Fracture Fixation, Internal
- Heparin, Low-Molecular-Weight
- Hip Fractures
- Postoperative Complications
- Venous Thrombosis
- Warfarin
Anatomy
- hip